I subgrupper bestående af kvinder og sorte patienter, henholdsvis 32% og 26% af den samlede forsøgspopulation, sås der ingen evidens for nyrefordel, selvom sikkerhedsintervallerne ikke udelukker det.
In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it.